Namir Hassan
Chief Executive Officer Zelluna
Namir Hassan joined Zelluna Immunotherapy in August 2018 to serve as Chief Scientific Officer and subsequently as Chief Executive Officer from 2019. He has over 15 years of biotech and pharma industry experience spanning target validation through to early phase clinical trials with most of that spent on Immunotherapies. Prior to joining Zelluna, Namir was a VP at Immunocore, responsible for creating and growing the infectious disease unit and pipeline. During his tenure, Namir was also responsible for overseeing and strategically expanding biology, preclinical, biomarkers and development for the Oncology portfolio and successfully leading the first-in-human study with KIMMTRAK, the first ever T Cell Receptor (TCR) bispecific subsequently approved for the treatment of uveal melanoma.
Seminars
- Reviewing how emerging clinical data is shaping market perspectives on in vivo cell therapies to guide smart pipeline decisions
- Examining the resurgence of next-generation in vivo CAR-Ts and ex vivo explorations for solid tumours and autoimmune disease to identify where each modality can unlock the greatest opportunity
- Aligning scientific, manufacturing, regulatory and commercial perspectives on the future direction of the field to accelerate clinical impact
- Harnessing TCR specificity and NK-cell biology to create a differentiated approach to solid tumour targeting
- Reviewing preclinical evidence supporting anti-tumour activity, durability, and translational potential
- Sharing clinical progress and safety findings to highlight the therapeutic potential of TCR-NK therapies in patients
